High-grade B-cell lymphoma

7 trials 3 recruiting MedDRA PT
7 Registered trials
3 Recruiting
5 Unique sponsors
13 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
H Endocrinology (ATC H) 1
L Oncology (ATC L) 4
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 2 substances
Antibody-drug conjugate (ADC) 2 substances
Unknown / small molecule 1 substance
Platinum compound 1 substance
Antimetabolite 1 substance
Corticosteroid 1 substance
IMiD 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (rat) 1 substance
Monoclonal antibody 1 substance
BTK inhibitor 1 substance
Phase III: 2 Phase II: 3 Phase I: 1 Phase I (First in Human): 1

Filter these 7 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 7 trials

Phase III

2 trials
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-508343-48-00 7 countries 2019 n=128
    Ended
  • University Of Saarland Academic
    ACALABRUTINIB
    2022-501187-18-00 2 countries 2023 n=360
    Recruiting

Phase II

3 trials
  • Instytut Hematologii I Transfuzjologii Academic
    AXICABTAGENE CILOLEUCEL; BENDAMUSTINE HYDROCHLORIDE; CISPLATIN; CYTARABINE; DEXAMETHASONE; LENALIDOMIDE; POLATUZUMAB VEDOTIN; RITUXIMAB; TAFASITAMAB
    2024-518275-64-00 1 country n=340 Orphan
    Pending
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-00 1 country n=104 Orphan
    Not authorised
  • Universitaet Muenster Academic
    EPCORITAMAB; LONCASTUXIMAB TESIRINE
    2023-509861-19-01 1 country 2025 n=104 Orphan
    Recruiting

Phase I

1 trial
  • Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic
    IMP not specified
    2023-507213-97-00 1 country 2024 n=52
    Recruiting

Phase I (First in Human)

1 trial
  • Novartis Pharma AG Commercial
    RAPCABTAGENE AUTOLEUCEL
    2023-507062-34-00 5 countries 2020 n=142
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 2 Phase III, Phase I (First in Human) 0
Universitaet Muenster Academic 2 Phase II 1
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Academic 1 Phase I 1
Instytut Hematologii I Transfuzjologii Academic 1 Phase II 0
University Of Saarland Academic 1 Phase III 1
New trials by year
2019
1
2020
1
2023
1
2024
1
2025
1
← All indication landscapes